Antiviral therapy for HCV using direct acting antiviral drugs in patients with chronic hepatitis C undergoing hemodialysis.

Antiviral therapy for HCV using direct acting antiviral drugs in patients with chronic hepatitis C undergoing hemodialysis. - Antiviral therapy for HCV using direct acting antiviral drugs in patients with chronic hepatitis C undergoing hemodialysis.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017023

Enrollment

150

Registered

2015-04-15

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with HCV genotype 1B infection who are undergoing maintenance hemodialysis.

Interventions

asunaprevir 200mg twice daily and daclatasvir 60mg once daily for 24 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with HCV genotype 1B infection who are undergoing maintenance hemodialysis.

Exclusion criteria

Exclusion criteria: Patients infected with HCV other than HCV genotype 1B. Patients with Child-Pugh class B or C cirrhosis.

Design outcomes

Primary

Measure	Time frame
Antiviral efficacy to eradicate HCV in patients with chronic HCV infection undergoing hemodialysis.	—

Secondary

Measure	Time frame
Safety of oral antiviral therapy in patients with chronic HCV infection undergoing hemodialysis.	—

Countries

Japan

Contacts

Public ContactHidenori Toyoda

Ogaki Municipal Hospital Gastroenterology

tkumada@he.mirai.ne.jp0584-81-3341(1561)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026